CAS: 18472-87-2; Phloxine B

相似化合物

17372-87-1 17372-87-1 17372-87-1

专利信息

专利号:US-8470932-B2
优先权日:2010-04-08
标题 :Scalable process for synthesis of a curable wax
发明人：ROBINSON SARAH J P; ENRIGHT THOMAS E; BELELIE JENNIFER L
权利人:ROBINSON SARAH J P; ENRIGHT THOMAS E; BELELIE JENNIFER L; XEROX CORP
摘要:The methods of manufacturing a curable wax, such as an acrylate of a hydroxyl-terminated polyethylene wax having the structure CH 3 —(CH 2 ) n —CH 2 OH, where n=22-24, are disclosed. The methods may include reacting a wax having a transformable functional group and a curable compound in the presence of an organic solvent to form an acrylate. The methods may further include removing excess curable compound using hot water having a temperature of more than 85° C., and solidifying the acrylate. The methods may thereby provide safe and cost effective methods for curable wax production at large scale.

专利号:US-8207274-B2
优先权日:2010-04-08
标 题 :Solvent-free process for synthesis of a curable wax
发明人：ROBINSON SARAH J P; ENRIGHT THOMAS E; BELELIE JENNIFER L
权利人:ROBINSON SARAH J P; ENRIGHT THOMAS E; BELELIE JENNIFER L; XEROX CORP
摘要:The methods of manufacturing a curable wax, such as an acrylate of a hydroxyl-terminated polyethylene wax having the structure CH3—(CH2)n—CH2OH, where n=22-24, and removing a fouled material in a reactor are disclosed. The methods may include reacting a wax having a transformable functional group and a curable compound in the absence of an organic solvent to form an acrylate. The methods may further include removing excess curable compound using hot water having a temperature of more than about 85° C., solidifying the acrylate, removing the acrylate, and removing a fouled material in the reactor by emulsification.

专利号:US-8802380-B2
优先权日:2007-06-04
标 题 :Method for testing or screening protein synthesis inhibitors
发明人：DREYFUSS GIDEON; KASIM MUMTAZ
权利人:DREYFUSS GIDEON; KASIM MUMTAZ; UNIV PENNSYLVANIA
摘要:This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.

专利号:US-2023097824-A1
优先权日:2020-05-08
标 题:Semi-synthesis and use of racemic hematoxylin
发明人：DURRANT EDWARD E; HEINDL DIETER; HUBER FLORIAN MAURITIUS ERASUMU; KLEIN ERIC; KOSMEDER II JEROME W; VOSS EDGAR
权利人:VENTANA MED SYST INC; ROCHE DIAGNOSTICS OPERATIONS INC
摘要:A racemic hematoxylin formulation is disclosed that includes one or both of a stabilizer compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process. Methods of using and making the stabilized composition also are disclosed.

专利号:WO-2012016973-A1
优先权日:2010-08-02
标 题:Invention related to contact allergens
发明人：SCHMIDT MARC; GOEBELER MATTHIAS; BADRINARAYANAN RAGHAVAN
权利人:TRANSMIT GMBH; SCHMIDT MARC; GOEBELER MATTHIAS; BADRINARAYANAN RAGHAVAN
摘要:The problem of the underlying invention is to foresee a new method and a new class of substances to treat and or reduce hypersensivity (CHS) with mammals, especially humans to nickel, especially Ni 2+ . Surprisingly it was found, that the site-specific h TLR4 inhibition as potential strategy for therapeutic intervention without affecting vital immune responses. Here we demonstrate that Ni 2+ induces an inflammatory response via direct activation of human Toll-like receptor 4 (hTLR4). Remarkably, Ni 2+ induces TLR4 activation is species-specific since mouse TLR4 (mTLR4) is incapable to generate this response. Studies with mutant TLR4 proteins revealed a requirement of the non-conserved histidines 456 and 458 of h TLR4 for activation by Ni 2+ but not by the natural ligand LPS. Accordingly, transgenic h TLR4 expression in Tlr4 -deficient mice allowed efficient sensitization to Ni 2+ and elicitation of CHS. Allergies to nickel (Ni 2+) are the most frequent cause of contact hypersensitivity (CHS) in industrialized countries. Both a T lymphocyte-specific signal and a proinflammatory signal are required for efficient CHS development. Here we demonstrate that Ni 2+ induces an inflammatory response via direct activation of human Toll-like receptor 4 (hTLR4). Remarkably, Ni 2+ induced TLR4 activation is species-specific since mouse TLR4 (m TLR4) is incapable to generate this response. Studies with mutant TLR4 proteins revealed a requirement of the non-conserved histidines 456 and 458 of h TLR4 for activation by Ni2+ but not by the natural ligand LPS. Accordingly, transgenic h TLR4 expression in Tlr4 -deficient mice allowed efficient sensitization to Ni 2+ and elicitation of CHS. Our data implicate site-specific h TLR4 inhibition as potential strategy for therapeutic intervention without affecting vital immune responses. Furthermore it is shown that hypersensitivity-related inflammatory response via direct activation of human Toll-like receptor 4 (h TLR4) is not only induced by nickel but also by cobalt (Co 2+ ). Moreover, the invention surprisingly describes synthesis of truncated h TLR4 molecules (s-h TLR4) missing the transmembrane domain and the C-terminal part of the protein that are applicable in a method for identification of substances to treat and or reduce hypersensitivity (CHS) or sepsis with mammals by inhibition of h TLR4 activation.

专利号:US-10772990-B2
优先权日:2014-04-01
标题 :Tissue filler compositions and methods of use
发明人：NIKOLIS ANDREAS; HERBERT LISE
权利人:KLOX TECH INC
摘要:The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.